Cardiora Pty Ltd

Level 9, 31 Queen St, Melbourne VIC 3000

ABN: 33 606 313 642

+613 9657 0700

CRD-102

Delivered orally, CRD-102 (extended release milrinone) is intended to provide clinicians with additional treatment options to ease the symptoms of end stage heart failure, improve quality of life and to reduce hospital re-admission rates in this patient group.

 

Milrinone is a Phosphodiesterase III inhibitor that acts by preventing the breakdown of cyclic AMP (cAMP). The increased levels of cAMP result in improved calcium movement within the cell providing both inotropic (improved contraction) and lusitropic (improved relaxation) properties.

 

Pipeline

 

Phase I

Phase II

Phase III

Heart Failure with

Preserved

Ejection Fraction

(HFpEF)

Heart Failure with

Reduced

Ejection Fraction

(HFrEF)

Left Ventricle Assist
Device induced

Right Heart Failure

(LVAD & RHF)*

1

* FDA IND trial